Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Amarin Corp ADR (AMRN)

Amarin Corp ADR (AMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 248,333
  • Shares Outstanding, K 410,672
  • Annual Sales, $ 306,910 K
  • Annual Income, $ -59,110 K
  • EBIT $ -44 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.92
  • Price/Sales 0.78
  • Price/Cash Flow N/A
  • Price/Book 0.45
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.09
  • Most Recent Earnings $-0.05 on 10/30/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 106.16% ( -46.44%)
  • Historical Volatility 43.71%
  • IV Percentile 26%
  • IV Rank 18.82%
  • IV High 499.67% on 08/05/24
  • IV Low 14.94% on 10/17/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 136
  • Volume Avg (30-Day) 290
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 43,751
  • Open Int (30-Day) 43,973

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.13
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -800.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5550 +10.83%
on 10/24/24
0.6641 -7.38%
on 10/29/24
+0.0093 (+1.54%)
since 10/04/24
3-Month
0.5550 +10.83%
on 10/24/24
0.7219 -14.79%
on 08/06/24
-0.0388 (-5.93%)
since 08/05/24
52-Week
0.5550 +10.83%
on 10/24/24
1.3700 -55.10%
on 01/30/24
-0.1131 (-15.53%)
since 11/03/23

Most Recent Stories

More News
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

Amarin Corporation plc AMRN reported an adjusted loss of 5 cents per share for the third quarter of 2024, which was in line with the Zacks Consensus Estimate. The company had reported breakeven earnings...

FOLD : 11.44 (+0.97%)
AMRN : 0.6190 (+2.36%)
ARDX : 5.80 (-1.53%)
ATNM : 1.7800 (+1.14%)
Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript

AMRN earnings call for the period ending September 30, 2024.

AMRN : 0.6190 (+2.36%)
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

AMRN : 0.6190 (+2.36%)
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript

AMRN earnings call for the period ending June 30, 2024.

AMRN : 0.6190 (+2.36%)
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript

AMRN earnings call for the period ending March 31, 2024.

AMRN : 0.6190 (+2.36%)
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

/CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

AMRN : 0.6190 (+2.36%)
HLS.TO : 3.32 (+0.61%)
Why Amarin Stock Was Rocketing Higher on Wednesday

There was unambigously good news about the company's single commercialized medication.

AMRN : 0.6190 (+2.36%)
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript

AMRN earnings call for the period ending December 31, 2023.

AMRN : 0.6190 (+2.36%)
Why Amarin Stock Skyrocketed Today

The biopharma company announced a big repurchase plan, along with strong preliminary Q4 results.

AMRN : 0.6190 (+2.36%)
Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript

AMRN earnings call for the period ending September 30, 2023.

AMRN : 0.6190 (+2.36%)

Business Summary

Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating...

See More

Key Turning Points

3rd Resistance Point 0.6630
2nd Resistance Point 0.6415
1st Resistance Point 0.6231
Last Price 0.6190
1st Support Level 0.5832
2nd Support Level 0.5617
3rd Support Level 0.5433

See More

52-Week High 1.3700
Fibonacci 61.8% 1.0587
Fibonacci 50% 0.9625
Fibonacci 38.2% 0.8663
Last Price 0.6190
52-Week Low 0.5550

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar